Cisplatin and etoposide are already used ... "While current chemotherapy regimes are effective for some women with ovarian cancer, many relapse later and overall cure rates are improving only ...

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival.

HRD is now used as a biomarker for administering PARP inhibitors or platinum-based chemotherapy (such as cisplatin or carboplatin) to ovarian cancer patients. PARP inhibitors, which are now used ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

This included ovarian cancer cells, which are known to develop resistance to cisplatin treatment in many cases. "Drug resistance is a significant challenge in cancer therapy," said Plebanski ...

Laura Everley, who was diagnosed with ovarian cancer in 2014, with her son Harry Only a third of women would see a doctor when they experience a major symptom of ovarian cancer, according to the ...

A new study from Cedars-Sinai Cancer reveals a potential way to overcome tumor resistance to a common chemotherapy drug ...

a chemotherapy agent used to treat triple negative breast cancer, as well as ovarian and head and neck cancers. Another drug that’s in short supply is cisplatin, which has been the backbone for ...